Compare the efficacy and safety of two combination regimens of miltefosine and paromomycin with the current standard treatment
current phase of drug development
updated 29 Feb 2020
Based on the good results of the miltefosine and paromomycin (MF+PM) combination in South Asia, and on the need for an alternative and safer treatment to replace SSG, a Phase III study was launched in 2018 to compare two combination regimens of MF+PM with the current standard visceral leishmaniasis treatment, SSG&PM.
If the combination is proven safe and efficacious, current treatment would no longer rely on SSG, an injectable drug, but would be replaced with miltefosine, an oral drug. A safer, more field-adapted, patient-friendly treatment would particularly benefit children, who represent a high proportion of the population at risk in East Africa.
News & press releases
Get our latest news, personal stories, research articles, and job opportunities.